INmune Bio Inc. Secures $13 Million Funding to Revolutionize Cancer Treatment with INKmune Therapy

INmune Bio Inc., a pioneering clinical stage immuno-oncology company, has successfully raised $13 million in its latest funding round, marking a significant milestone in its mission to revolutionize cancer treatment. Specializing in leveraging the power of the patient’s immune system, INmune has developed INKmune, an innovative therapy designed to prime natural killer (NK) cells to effectively target and destroy cancer cells. This funding will primarily be directed towards advancing INKmune through clinical trials, with a particular focus on combating residual disease—the hidden cancer cells that can survive initial therapies and lead to relapses. By honing in on this critical aspect of cancer treatment, INmune aims to significantly improve patient outcomes and extend survival times. The company employs a precision medicine approach, utilizing a novel mechanism of action that enhances the abilities of NK cells to eliminate these persistent threats. This financial boost not only underscores investor confidence in INmune’s pioneering research and development initiatives but also positions the company closer to delivering transformative solutions for patients battling cancer. As INmune embarks on this next phase of its journey, the funding will facilitate the continued exploration of its growing portfolio, which includes various drug candidates such as XPro1595, Quellor, LIVNate, and INB03—further underscoring the company's commitment to advancing cancer care. While INmune Bio's therapies have not yet received regulatory approval, the focus on harnessing the immune system's potential offers a promising path forward in the fight against cancer.